Close Menu

NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its fourth quarter revenues rose 88 percent year over year, thanks largely to a 120 percent increase in testing services revenues.

For the three months ended Dec. 31, 2018 the transplant diagnostics company reported total revenues of $23.5 million, up from $12.5 million a year earlier, and beat the average Wall Street analyst estimate of $23.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.

Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.

The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.

In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.